ArticleHuman immunology2010
Transcript abundance patterns in Kawasaki disease patients with intravenous immunoglobulin resistance.
Article in Human immunology, 2010. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 57 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
57 citing papers in PubMed, 1 synthesis or guideline pooled it, 100 citations in OpenAlex.
- Prevalence of IVIG resistance in Kawasaki disease: a systematic review and meta-analysis.Frontiers in pediatrics · 2025Pooled it
- Phase I/IIa Trial of Atorvastatin in Patients with Acute Kawasaki Disease with Coronary Artery Aneurysm.The Journal of pediatrics · 2019Trial
- Monocyte Single-Cell-Type Gene Expression Analysis Differentiates Kawasaki Disease From Viral Infection With High Specificity.Journal of cellular and molecular medicine · 2026Article
- Protective role of complement signaling in Kawasaki disease vasculitis.JCI insight · 2026Article
- Sirtuin 1 Activation Mitigates Murine Vasculitis Severity by Promoting Mitophagy.Circulation research · 2026Article
- TREM-1-Associated Neutrophil Extracellular Trap Formation is Linked to IVIG Resistance in Kawasaki Disease: A Convergent Transcriptomic and Prospective Validation Study.Journal of clinical immunology · 2026Article
- IL-33 blockade attenuates vascular inflammation in a mouse model of Kawasaki disease vasculitis.Clinical and experimental immunology · 2026Article
- The diagnostic accuracy of CC chemokine ligand 23 for Kawasaki disease.Frontiers in immunology · 2026Article
- Itaconate ameliorates cardiovascular inflammation in a mouse model of Kawasaki disease vasculitis - brief report.Frontiers in immunology · 2026Article
- Anakinra for infants under six months with Kawasaki disease and coronary artery lesions: a multicenter case series and literature review.Pediatric rheumatology online journal · 2025Article
- Sirtuin 1 Activation Mitigates Murine Vasculitis Severity by Promoting Autophagy and Mitophagy.bioRxiv : the preprint server for biology · 2025Article
- Identification of key ferroptosis‑related biomarkers in Kawasaki disease by clinical and experimental validation.Biomedical reports · 2025Article
- Single-cell transcriptomic analysis reveals a systemic immune dysregulation in intravenous immunoglobulin non-responsive Kawasaki disease.Frontiers in immunology · 2025Article
- Expression of Serum Ferritin, Human neutrophil lipocalin, Procalcitonin, and inflammatory factors in children with Kawasaki disease and their relationship to coronary artery lesions.American journal of translational research · 2025Article
- The Central Role of Interleukin-1 Signalling in the Pathogenesis of Kawasaki Disease Vasculitis: Path to Translation.The Canadian journal of cardiology · 2024Review
- Kawasaki Disease-Associated Cytokine Storm Syndrome.Advances in experimental medicine and biology · 2024Review
- Platelets exacerbate cardiovascular inflammation in a murine model of Kawasaki disease vasculitis.JCI insight · 2023Article
- Article
- Identification of Hub Biomarkers and Immune and Inflammation Pathways Contributing to Kawasaki Disease Progression with RT-qPCR Verification.Journal of immunology research · 2023Article
- Identifying differentially expressed genes and miRNAs in Kawasaki disease by bioinformatics analysis.Scientific reports · 2022Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
12 authors at 3 institutions in 1 country.
Funding
Abstract
Intravenous immunoglobulin (IVIG)-resistant Kawasaki disease (KD) patients comprise at least 20% of treated patients and are at high risk for coronary artery abnormalities. If identified early in the course of the disease, such patients may benefit from additional anti-inflammatory therapy. The aim of this study was to compare the transcript abundance between IVIG resistant and -responsive KD patients, to identify biomarkers that might differentiate between these two groups and to generate new targets for therapies in IVIG resistant KD patients. We compared the transcript abundance profiles of whole-blood RNA on Agilent arrays from acute and convalescent KD subjects and age-similar, healthy controls. KD subjects were stratified as IVIG resistant or -responsive based on response to initial IVIG therapy. Transcript abundance was higher for IL-1 pathway genes (IL-1 receptor, interleukin receptor associated kinase, p38 mitogen-activated protein kinase), and MMP-8. These findings point to candidate biomarkers that may predict IVIG resistance in acute KD patients. The results also underscore the importance of the IL-1 pathway as a mediator of inflammation in KD and suggest that IL-1 or its receptor may be reasonable targets for therapy, particularly for IVIG resistant patients.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.